The Analyst's Optimism and the Investor's Scrutiny
Anthem Biosciences has garnered a 'BUY' recommendation and a target price of INR 755 from Prabhudas Lilladher, suggesting a potential 16% upside. This optimistic outlook is predicated on a deep pipeline, expected ramp-up in specialty ingredients, and significant capital expenditure plans to support future growth. The company is projected to achieve a Compound Annual Growth Rate (CAGR) of approximately 21% for revenue and 18% for profit after tax between fiscal years 2026 and 2028. However, this growth narrative is shadowed by Anthem's demanding valuation metrics. As of late March 2026, the stock trades at a trailing Price-to-Earnings (P/E) ratio exceeding 73x and a Price-to-Book (P/B) ratio of over 13x, accompanied by a market capitalization nearing ₹38,264 crore. These figures significantly outpace established players in the Contract Research, Development, and Manufacturing Organization (CRDMO) space.
Valuation Reckoning Against Peers
The CRDMO sector in India is indeed experiencing strong tailwinds, with projections indicating a 13% CAGR through FY24-FY29, driven by global supply chain diversification and increasing outsourcing demand. Companies like Divis Laboratories, a benchmark in API manufacturing, trade at a P/E of around 65x and an EV/EBITDA of ~43x. Syngene International, another significant CRDMO player, trades at a P/E of approximately 52x and a much lower EV/EBITDA of ~15.9x. Even Laurus Labs, while also trading at a premium with a P/E around 65x, has an EV/EBITDA of ~34x and a P/B ratio that, while elevated, is not as stretched as Anthem's. Anthem Biosciences' valuation multiples suggest that the market has already priced in a substantial portion of its future growth, potentially leaving less room for upside and increasing risk.
The Bear Case: Expensive Growth and Mixed Signals
While analysts like Prabhudas Lilladher are initiating coverage with a bullish stance, a more critical perspective emerges from independent analysis. MarketsMojo recently downgraded Anthem Biosciences to a 'Sell' rating, citing a "very expensive" valuation and negative financial trends. This bearish assessment is supported by the stock's performance, having declined approximately 13% over the past 52 weeks, despite overall sector optimism. The high P/E and P/B ratios, particularly when compared to peers with similar or stronger market positions, suggest that the stock may be trading at a significant premium that is difficult to justify based on current financial trends. Furthermore, the recent resignation of the General Counsel, effective March 31, 2026, adds a minor governance footnote, though it does not appear to impact the core valuation debate. The divergence between a bullish initiation and a bearish independent rating highlights the polarized investor sentiment and the considerable risk embedded in the current valuation.
Future Outlook and Persistent Valuation Concerns
Despite the valuation concerns, the broader CRDMO sector outlook remains positive, with India expected to capture a larger share of the global market. Analysts project an average 12-month price target for Anthem Biosciences around INR 776.60, implying an 18.34% potential upside. However, this target is based on the assumption that the company can continue to execute on its growth strategy and that the current high valuation multiples can be sustained or expanded. Investors must weigh the projected growth against the steep valuation and the cautionary 'Sell' rating from MarketsMojo. The company's ability to deliver on its ambitious capex plans and capitalize on the GLP-1 API ramp-up will be critical, but the current market price may already reflect an overly optimistic scenario, making it vulnerable to any execution missteps or shifts in market sentiment.